<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347756">
  <stage>Registered</stage>
  <submitdate>1/12/2011</submitdate>
  <approvaldate>4/01/2012</approvaldate>
  <actrnumber>ACTRN12612000014853</actrnumber>
  <trial_identification>
    <studytitle>A study to evaluate a new treatment protocol for post operative orthopaedic constipation</studytitle>
    <scientifictitle>The effect of an evidence based bowel protocol on time taken to return to normal bowel function in post operative major joint replacement patients</scientifictitle>
    <utrn>U1111-1126-0176</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>post operative constipation in major joint replacement patients</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients at intervention hospitals to receive a post operative bowel protocol based on the adminstration of polyethylene glycol with electrolytes (Movicol) according to bowel type as per the Bristol Stool Chart (BSC).  Dosage of Movicol depends on BSC number but maximum dose is one sachet (13.125g Macrogol 3350) per day in two divided doses.  This powder is dissolved in 125 ml of water.  The intervention lasts for the duration of the inpatient stay usually maximum of 8 days.</interventions>
    <comparator>Patients at the five control hospitals are to receive bowel management as per that hospital's current regime.  This regime is very variable depending on doctor, nurse, hospital and patient preference therefore I am unable to describe it here.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time taken (in days) to return to baseline bowel function</outcome>
      <timepoint>before discharge from hospital, at one week post discharge and at two weeks post discharge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients undergoing total hip or knee replacement</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>history or Crohns disease, toxic megacolon, pregnant or breastfeeding, known allergy to polyethylene glycol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients whose orthopaedic surgeon has consented, who are seen in the hospital pre-admission clinic and who are having total hip or total knee surgeon are eligible to participate in the study.  This study is a cluster randomised study so of the seven hospitals participating each was randomised (by a biostatastician) into either a control or intervention hospital with each hospital aware of its randomisation.
Allocation is not concealed.</concealment>
    <sequence>not applicable as hospitals were randomised, not patients.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/05/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>320</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>6230</postcode>
    <postcode>3350</postcode>
    <postcode>3550</postcode>
    <postcode>6008</postcode>
    <postcode>3806</postcode>
    <postcode>3220</postcode>
    <postcode>3280</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St John of God Health Care</primarysponsorname>
    <primarysponsoraddress>111 Coventry Street, South Melbourne, Victoria, 3205</primarysponsoraddress>
    <primarysponsorcountry>Afghanistan</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St John of God Health Care</fundingname>
      <fundingaddress>111 Coventry Street, South Melbourne, Victoria, 3205</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Notre Dame Australia</othercollaboratorname>
      <othercollaboratoraddress>PO Box 1225
FREMANTLE
Western Australia 6959</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is determine whether the administration of polyethylene glycol (Movicol) to post operative total hip and total knee replacement patients results in faster return to normal in the intervention group.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Notre Dame Australia</ethicname>
      <ethicaddress>PO Box 1225
FREMANTLE
Western Australia 6959</ethicaddress>
      <ethicapprovaldate>12/01/2011</ethicapprovaldate>
      <hrec>010145F</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gail Ross-Adjie</name>
      <address>St John of God Hospital
100 Murdoch Drive
Murdoch  Western Australia 6150</address>
      <phone>+61 08 93339751</phone>
      <fax />
      <email>Gail.Ross-Adjie@sjog.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Gail Ross-Adjie</name>
      <address>St John of God Hospital
100 Murdoch Drive
Murdoch  Western Australia 6150</address>
      <phone>+61 08 93339751</phone>
      <fax />
      <email>Gail.Ross-Adjie@sjog.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Gail Ross-Adjie</name>
      <address>St John of God Hospital
100 Murdoch Drive
Murdoch  Western Australia 6150</address>
      <phone>+61 08 93339751</phone>
      <fax />
      <email>Gail.Ross-Adjie@sjog.org.au</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>